Revance Therapeutics, Inc. to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021
January 25, 2021 at 06:30 pm IST
Share
Revance Therapeutics, Inc. announced that three ePosters will be presented at the Maui Derm for Dermatologists 2021 meeting being held in-person at the Grand Wailea in Maui, Hawaii from January 25-29, 2021 and broadcasted via live-stream for those unable to join in person. The presentations will showcase findings from the open-label Phase 2 study evaluating DaxibotulinumtoxinA for Injection for the simultaneous treatment of moderate to severe upper facial lines (glabellar lines, forehead lines and lateral canthal lines), as well as data demonstrating the progressive effects of DaxibotulinumtoxinA for Injection on static/resting, glabellar lines with repeated treatment as a secondary analysis of data from the SAKURA Phase 3 program. Additionally, results of an in vitro study evaluating the ability of recombinant hyaluronidase to degrade the RHA® Collection of hyaluronic acid based dermal fillers, alongside a number of other commercially available HA fillers will be shared. The following ePosters are currently available to attendees and the abstracts are available online via the Maui Derm website at MauiDerm.com. Title: Treatment of Upper Facial Lines with DaxibotulinumtoxinA for Injection: Results from an Open-label Phase 2 Study. Authors and Affiliations: Jeffrey S. Dover, Skincare Physicians, Chestnut Hill Massachusetts; Shannon Humphrey, University of British Columbia, Vancouver, British Columbia; Z. Paul Lorenc, Department of Plastic Surgery, Lenox Hill Hospital, New York New York; Ava Shamban, AVA MD, Santa Monica, California; Todd Gross, Yan Liu, Roman Rubio, Domenico Vitarella, Revance Therapeutics, Inc.Newark, California. Title: DaxibotulinumtoxinA for Injection–treated Subjects Show Progressive Improvement in Static Glabellar Lines with Repeated Treatment. Authorsand Affiliations:Richard Glogau, Department of Dermatology, University of California at San Francisco, San Francisco, California; Theda Kontis, Department of Otolaryngology-Head and Neck Surgery, Division of Facial Plastic and Reconstructive Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland; Yan Liu, Conor J. Gallagher, Revance Therapeutics, Inc.Newark, California. Title: An in vitro Kinetic Study of Hyaluronic Acid Filler Enzymatic Degradation to Human Recombinant Hyaluronidase. Authorsand Affiliations: Jimmy Faivre, Teoxane, Mélanie Gallet, Teoxane, Conor Gallagher, Revance Therapeutics, François Bourdon, Teoxane.
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Revance Therapeutics, Inc. to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021